ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Biogen’s Imraldi, an adalimumab biosimilar candidate referencing Humira, granted positive opinion by
June 27, 2017If approved, Imraldi will be the third anti-TNF biosimilar in Biogen’s portfolio in Europe. -
Biogen Acquires Remedy Pharmaceuticals’ Cirara for Large Hemispheric Stroke
May 16, 2017Biogen announced it has completed an asset purchase of Remedy Pharmaceuticals’ Phase 3 candidate, Cirara (intravenous glyburide). -
US patent office upholds Biogen's patent for Tecfidera
March 22, 2017The US Patent and Trademarks Office's Patent Trial and Appeal Board on Tuesday upheld the validity of a patent protecting Biogen's multiple sclerosis treatment Tecfidera (dimethyl fumarate) following a challenge by hedge fund manager Kyle Bass. -
Biogen Appoints RED SVP
March 20, 2017Ghosh will lead discovery and development efforts from idea through proof of concept -
Biogen reaches $1.25-billion settlement, licensing agreement with Forward Pharma in MS drug patent d
January 18, 2017Biogen announced Tuesday that it has agreed to enter a $1.25-billion settlement and licensing agreement with Forward Pharma under which it will obtain an irrevocable license to all of the latter's intellectual property.
Pharma Sources Insight January 2025
